# Antiviral Drugs on the Treatment of SARS-CoV-2

> **NCT04727775** · — · COMPLETED · sponsor: **Astana Medical University** · enrollment: 150 (actual)

## Conditions studied

- Complication of Medical Care
- Pneumonia, Viral

## Interventions

- **DRUG:** Favipiravir
- **DRUG:** Remdesivir

## Key facts

- **NCT ID:** NCT04727775
- **Lead sponsor:** Astana Medical University
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2020-12-01
- **Primary completion:** 2023-07-25
- **Final completion:** 2023-07-25
- **Target enrollment:** 150 (ACTUAL)
- **Last updated:** 2023-08-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04727775

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04727775, "Antiviral Drugs on the Treatment of SARS-CoV-2". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04727775. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*